Why Pfizer's Deal With Beam Therapeutics Is a Smart Move

Submitted by admin on January 24, 2022 - 10:12am

Source:

Motley Fool

News Tags:

Headline:

snippet:

Pfizer is paying $300 million upfront to Beam to use its base-editing technology on three programs targeting rare genetic diseases.
Beam benefits from a big influx of cash without having to give up any of its own pipeline candidates.
Pfizer gains access to Beam's promising technology without having to spend a fortune to acquire the company.

Search form